Kornimate/medical-research-clean huggingface dataset:
hematologic profile, vit. b12 and folic acid in cirrhotics received sofosbuvir and daclatasvir with or without ribavirin

Conditions: Liver Cirrhoses; Chronic Hepatitis c; Directly Acting Antivirals

Summary: use of ribavirin could affect hematologic profile of the patients negatively. with advent of new antiviral therapy, the preexisting hematologic changes may alter or corrected after treatment. however, this point is still not properly studied.

hepatitis c virus (hcv) infection is a global health problem that affects 170 million people worldwide, and approximately 55% (95 million) of the infected population is in south east asia and western pacific countries. hepatitis c virus (hcv) is considered one of the main causes of chronic hepatitis and also may be complicated by serious complications as liver cirrhosis, ascites and hepatocellular carcinoma. it is also, one of the leading indications for liver transplantation (lt) in adults around the world. abnormalities in hematological parameters are common in patients with cirrhosis. the pathogenesis of abnormal hematological indices (his) in cirrhosis is multifactorial and includes portal hypertension-induced sequestration, alterations in bone marrow stimulating factors, viral- and toxin-induced bone marrow suppression and consumption or loss. abnormalities in his are associated with an increased risk of complications including bleeding and infection. so, early recognition and early treatment of those patients with chronic hcv infection can modify its natural history. there are many factors affecting the outcome of hcv infection as viral, environmental and host factors, including immunologic and genetic susceptibilities. till 2011, the main lines of therapy were interferon plus ribavirin for at least 48 weeks but these combinations was associated with low incidence of sustained virological response (svr). now, there is era of direct acting analogues that used for treatment of patients with chronic hcv infection and associated with high rate of svr. daclatasvir is a first-in-class hcv ns5a replication complex inhibitor, and sofosbuvir is a nucleotide analogue hcv ns5b polymerase inhibitor. both have potent antiviral activity and broad genotypic coverage and are administered orally once daily.

Eligibility criteria:
inclusion criteria: * patients known to have hcv-related liver cirrhosis and candidate for therapy with sofosbuvir and daclatasvir with or without ribavirin exclusion criteria: * chronic hepatitis due causes other than chronic hcv infection * coinfection with hiv or hbv infection * hepatocellular carcinoma * decompensated cirrhosis
survey of lifelong food and nutrition assistance (lifana) in stroke patients and caregivers

Conditions: Stroke; Relatives; Diet Modification

Summary: many elderly suffer from nutritional problems that can cause (or can be caused by) a number of complications such as weakened immune systems and chronic health conditions (diabetes type 2, high blood pressure, cardiovascular diseases or even osteoporosis). through appropriate adjustments in the diets, on the basis of nutritional advice, the burden of established diseases as well as the risks of developing further conditions can be diminished. the goal of our proposed project lifana is to develop and evaluate the lifana nutrition solution to support healthy nutrition.. this may include general preferences, such as culture, taste, and budget, but more importantly automated and personalised nutritional recommendations based on advice provided by professional nutritionists and allergists. this is a national project co-funded by the european union. one of the activities of the project is to collect information through a survey with patients. these questions will contribute to creating solutions that can explore the perspectives of patients.

patients will be approached in the clinic by a neurologist and health care professionals. the questionnaire will take place at cereneo. the group will consist of 25 participants and last between 1h. the survey will be conducted by a clinician who will take notes. semi-structured discussion guide will be used. with regard to the communication, the moderator will identify factors that will influence communication in a positive or negative way. the health professionals will perform content analyses on the transcripts; the schema of categories will be oriented towards the research questions, using open questions, directly addressing quiet participants, and handling the discussion guide in a flexible way.

Eligibility criteria:
inclusion criteria: * stroke patients undergoing rehabilitation * caregivers of stroke patients exclusion criteria: * severe aphasia * severe cognitive deficits

Keywords: stroke rehabilitation personalized nutrition mobile-health stroke
bimodal and coaxial high resolution ophtalmic imaging

Conditions: Retinitis Pigmentosa; Maculopathy, Age Related; Macular Dystrophy; Macular Edema; Retinal Detachment; Retinal Degeneration; Glaucoma; Vascular Inflammation; Hypertension; Stroke; Diabetes

Summary: the knowledge of the pathogenesis of retinal affections, a major cause of blindness, has greatly benefited from recent advances in retinal imaging. however, optical aberrations of the ocular media limit the resolution that can be achieved by current techniques. the use of an adaptive optics system improves the resolution of ophthalmoscopes by several orders of magnitude, allowing the visualization of many retinal microstructures: photoreceptors, vessels, bundles of nerve fibers. recently, the development of the coupling of the two main imaging techniques, the adaptive optics ophthalmoscope with optical coherence tomography, enables unparalleled three-dimensional in vivo cell-scale imaging, while remaining comfortable for the patients. the purpose of this project is to evaluate the performance of this system for imaging micrometric retinal structures.

the goal of the project is the capture and analysis of images with aoslo system, in order to evaluate the performance of this system compared to oct imaging devices and existing adaptive optics used at national hospital of ophthalmology.

Eligibility criteria:
inclusion criteria: * people over 18 * patient with a pathology affecting the eye or healthy volunteer * participant who signed the consent * beneficiaries of the health insurance exclusion criteria * patients with a history of photosensitivity. * patients who have just received a photodynamic therapy treatment * patients taking drugs with photosensitivity as a side effect. * persons with pacemakers or other implanted electronic medical device * patients with viral conjunctivitis or any other infectious disease. * patients with skin lesions on the neck or forehead * patients at high risk of damage from optical radiation, such as aphakic patients, or patients with decreased sensitivity to light due to fundus disease. * participant unable to be followed throughout the study * advanced cataract or severe opacities in the anterior segment of the eye.
increasing smoking cessation counselling in primary care using a chronic disease management system

Conditions: Delivery of Health Care; Smoking Cessation

Summary: this pilot study will determine the feasibility of studying a new smoking cessation management module in an existing chronic disease management system. the new module is intended to help healthcare providers deliver more smoking cessation counselling to their patients.


Eligibility criteria:
inclusion criteria: * physician subscribers to p-prompt cdms exclusion criteria: * paper users * physicians expected to retire during the course of the study * physicians whose billing files are not set-up with datasynch

Keywords: primary health care delivery of health care smoking cessation chronic disease disease management pilot projects
microbial colonization and change of chronic keratinized hand eczema after using halometasone triclosan

Conditions: Chronic Hand Eczema

Summary: the clinical study of the microbial colonization of chronic keratinized hand eczema and the change of microbial colonization after external using of halometasone triclosan cream

the clinical study of the microbial colonization of chronic keratinized hand eczema and the change of microbial colonization after external using of halometasone triclosan cream

Eligibility criteria:
inclusion criteria: * age ≥ 18 years * chronic keratinized hand eczema for at least 3 months * the affected area is greater than 30% * overall assessment of the severity of the disease(iga)≥3 or hees≥13 * no obvious incentive .who have read the instructions of the subject, agreed to and signed written informed consent, and have been able to provide a personal medical history. exclusion criteria: * pregnancy, breast feeding * severe liver and kidney disease, blood system disease, autoimmune disease, chronic severe infection, diabetes, mental illness, drug use, alcohol abuse, etc * malignant neoplasms or other serious maladies that may affect the correct assessment of efficacy * topical corticosteroid was suspended for less than 2 weeks;the system used corticosteroids and other immunosuppressive agents (thunder vine and other drugs) which were suspended for less than four weeks * eczema of the facial and skin creases * atopic dermatitis, contact dermatitis, blister hand eczema, contact urticaria, discoid eczema * participated in other clinical trials within 3 months. * known sensitivity to halometasone triclosan * failure to follow the prescribed medication or the incomplete record of the test process which will affect the curative effect judgment * other reasons why researchers think they should not be included
study evaluating the potential interaction between verapamil immediate release and sam-531 when co-administered

Conditions: Alzheimer Disease

Summary: the purpose of this study is to evaluate the effects of multiple doses of verapamil on the plasma concentration of a single dose of sam-531 in healthy young adult subjects and to assess the safety and tolerability of co-administration of sam-531 and verapamil.


Eligibility criteria:
inclusion criteria : 1. body mass index in the range of 18 to 30 kg/m2 and body weight greater than 50 kg. 2. healthy as determined by the investigator on the basis of medical history, physical examination findings, clinical laboratory test results, vital sign measurements, and digital 12-lead ecg readings. exclusion criteria : 1. presence or history of any disorder that may prevent the successful completion of the study. 2. any significant cardiovascular, hepatic, renal, respiratory, gastrointestinal (gi), endocrine, immunologic, dermatologic, hematologic, neurologic, or psychiatric disease.
more individualized care: assessment and recovery through engagement

Conditions: Depression; Anxiety; Opioid-Related Disorders; Pain, Chronic

Summary: the mi-care trial tests 12 months of telephone-based nurse care management for patients with depressive symptoms who take or have taken opioids at some time. the study tests whether offering nurse support to the patient and their primary care team that addresses these things and related issues can improve patients' health and well-being. eligible subjects are identified automatically using health system data and randomly assigned 50:50 to either a no-contact usual care arm or to the arm offered the mi-care program.


Eligibility criteria:
inclusion criteria eligible patients must meet all 4 criteria: 1. ≥1 in person or virtual encounter in a primary care setting in the 365 days prior to the data extraction date (pull date); 2. age ≥18 years at the pull date; 3. ≥1 phq-9 depression screening score of ≥10 within the 7 days prior to the pull date. 4. evidence of potential oud in the 365 days prior to and including the date of the qualifying phq-9 score. any 1 of the following qualifies as evidence of potential oud: 1. ≥1 active oud icd-10 diagnosis code in any setting except labs; 2. ≥1 prescription (orders or dispensed) for buprenorphine (oral formulations indicated for oud, extended release injectable, and implant); 3. ≥1 procedure code for buprenorphine (oral formulations indicated for oud, extended release injectable, and implant); 4. ≥1 icd-10 codes for opioid overdose; 5. ≥1 oud icd-10 code, including remission, and prescription (orders or dispensed) or procedure code for injectable naltrexone. exclusion criteria patients are ineligible who meet any of the criteria below: 1. the only indication of oud or only phq available to determine eligibility came from data protected under 42 cfr part 2; 2. the patient has already been randomized to the trial or was outreached in the pilot study (including outreach to the primary care provider only); 3. english interpreter required (per health system records). 4. any one of the following conditions in the 2 years prior to and including the date of the qualifying phq: 1. alzheimer's disease or dementia diagnosis. 2. medication to treat alzheimer's or dementia. (b) severe cognitive limitations. 5. current active treatment for cancer with chemotherapy or radiation therapy in the past 3 months (not including non-melanoma skin cancers). 6. previously requested to not participate in research studies at the health system; 7. documentation of hospice care in the 2 years prior to and including the date of the qualifying phq score; 8. patient is actively being outreached for (or is participating in) depression care management (kaiser permanente washington only)

Keywords: primary health care primary care primary care nursing evidence-based care depressive symptoms anxiety disorders and symptoms mental health mental health disorder opioid use opioid misuse opioid use disorder opioid dependence buprenorphine substance use disorders overdose overdose of opiate opioid overdose motivational interviewing brief psychotherapy
botulinum toxin-a for sialorrhoea treatment in asian adults with neurological diseases

Conditions: Sialorrhea

Summary: the efficacy of botulinum toxin a (bont-a) in asian population has not been properly studied and there is no literature available on the most efficacious dose of bont-a for sialorrhoea treatment. this research is aimed to find the dose of dysport® that would be efficacious without treatment-related adverse events and the duration of effectiveness of the drug for sialorrhea treatment in malaysian patients. the efficacy, safety, tolerability and adverse effects of three doses of dysport®(50mu, 100mu and 200mu) are examined at 2,6,12 and 24 weeks post injection in this double-blinding, randomized trial.

study objectives: to determine the efficacy, safety, tolerability and adverse effects of three doses of dysport® (50mu, 100mu and 200mu) in the treatment of sialorrhoea in asian patients with neurological disorders/diseases and to determine the most efficacious dose. study design: dose-ranging double blind pilot study. sample size: at least 30 adult patients with various neurological disorders complicated with sialorrhoea including stroke, motor neurone disease, traumatic brain injury and parkinsonism would be divided into 3 dosing groups. study method: patients who satisfy inclusion criteria and have given informed consent would be randomized into 3 equal groups given different total doses-50mu, 100mu, 200mu. the total dose will be divided equally and give to each of 4 salivary glands viz. the submandibular and parotid gland bilaterally. for example, if 200mu is to be given in total, 50mu would be given to each gland. injections would be given via a 25g needle to each gland with ultrasound guidance for better needle placement. one site will be injected per gland. primary outcome measure the percentage reduction in the rate of saliva production (as measured by difference in mean weight of dental rolls per minute from baseline) for each of the groups given different doses of dysport® at 2,6,12 and 24 weeks post injection. secondary outcome measure 1. patient's subjective assessment of improvement in sialorrhoea using the drooling frequency and severity scale (thomas-stonell scale) at 2,6,12 and 24 weeks post-injection. 2. duration to maximum reduction in salivation (as measured by the maximum reduction in weight of dental rolls)

Eligibility criteria:
inclusion criteria: 1. patients ≥ 18 years old. 2. patients with neurological disorder including stroke, motor neurone disease, traumatic brain injury and parkinsonism, diagnosis confirmed clinically by their treating physicians. 3. patients with a thomas-stonell drooling frequency and severity scale combined drooling ranking of ≥5. 4. patients who are able to give signed informed consent and are willing and able to comply with scheduled visits, treatment plan and other study procedure. exclusion criteria: 1. patients who are pregnant. 2. patients with bleeding disorders or who are on anticoagulants.

Keywords: botulinum toxin sialorrhoea drooling
the effects of lowering dietary carbohydrates on health, exercise performance and wellbeing-related outcomes

Conditions: Obesity; Diet Modification

Summary: the aim of the study is to investigate the long-term effects of the ketogenic diet and exercise (including interactions) on health markers, exercise performance and wellbeing outcomes in sedentary overweight individuals.

intentional nutritional ketosis induced by the low carbohydrate diet is an intensively discussed topic of many scientific as well as non-scientific discussions throughout the areas of healthy living, the sports sciences and often used now for the prevention and treatment of chronic diseases. it has been demonstrated that long-term low-carbohydrate diet is more effective for weight loss and cardiovascular and metabolic risk factor reduction than a low-fat diet. in light of conflicting theories of best practice surrounding a polarized topic that impacts human health and daily work performance, the primary aim of this research project is to examine how low-carbohydrate ketogenic diets affect health markers, exercise performance and wellbeing outcomes in sedentary overweight individuals. each study subject will be randomized into one of the four arms of the study and will undergo a 12-week intervention, with the exception of the study subjects in the control group, who will undergo no intervention for the period of 12 weeks. the project outcomes are of immense importance for the investigator's global human health, focus on a unique holistic perspective and have the potential to contribute towards much-needed adjustments in public health recommendations.

Eligibility criteria:
inclusion criteria: * bmi 25.00 - 40.00 kg/m2 * non-smokers * non-excessive alcohol intake (self-reported, ≥ to 2 drinks/day for men or ≥1 drink/day for women) * willing to accept random assignment * low active individuals over the last 1 year, i.e. no specific sports training or regular exercise (up to once a week) and self-reported physical activity \< 150 min/week (ipaq) * no evidence of liver, renal, metabolic, and cardiopulmonary disease and dis-eases contraindicating physical activity, no cancer, no psychiatric illness * physical activity readiness questionnaire (par-q) pass * body weight stable for the last 2 months and not actively on a weight loss plan * prediabetes state allowed (impaired fasting glucose level, i.e. 5.6 - 6.9 mmol/l; hba1c 5.7 - 6.4 %) exclusion criteria: * pregnancy, lactation * any specific diet (e.g. vegetarian) * use of hypoglycemic, lipid-lowering, antihypertensive, psychiatric medications or medications known to affect body weight or energy expenditure; any medication not noted allowed if the individual had been stable while taking such medication for at least 3 months prior to baseline data collection

Keywords: ketogenic diet carbohydrates chronic diseases physical activity fatigue mood wellbeing
resynchronization for ambulatory heart failure trial - lv endocardial

Conditions: Heart Failure, Left Ventricular Dysfunction

Summary: this trial will compare two strategies for patients with heart failure, left ventricular systolic dysfunction, and intermediate qrs durations. the control group is conventional crt. the experimental group is lvendo crt

patients randomized to the conventional crt will receive a crt device with or without icd. device implantation will be performed within 10 working days of randomization. patients randomized to lv endocardial crt will receive a crt device with or without icd, placed in the same time frame and will have ra and rv leads implanted as the conventional crt group. the device will be implanted in a facility that has the capacity to perform trans-atrial septal puncture with ultrasound guidance. the lv lead will be placed using a trans-atrial septal approach using a specially designed puncture tools and lvendo delivery tool kits specifically designed for this study

Eligibility criteria:
inclusion criteria: * patients with nyha class ii or iii or ambulatory iv hf symptoms * optimal hf medical therapy of at least 3 months (2009 accf/aha, esc 2012) * lvef less than or equal to 35% * sinus rhythm (can have paroxysmal atrial fibrillation) * qrs morphology is non-rbbb * qrs durations more than or equal to 120 ms, but less than 150 ms * patients are able to receive chronic oral anticoagulation * patients with pacemaker or icd that meet the above criteria may be upgraded to crt-d or crt-p exclusion criteria: * planned atrial fibrillation ablation within 12 months * patients with mitral or tricuspid prosthetic valve that precludes the placement of an lv lead transvenously or trans-septally * patients with rbbb * patients with lv thrombus * patients with permanent atrial fibrillation * patients with contraindications to oral anti-coagulation * in-hospital patients with acute cardiac or non-cardiac illness that requires intensive care * acute coronary syndrome (including mi) \< 4 weeks * coronary revascularization (cabg or pci) \< 3 months * uncorrected or uncorrectable primary valvular disease * restrictive, hypertrophic or reversible form of cardiomyopathy * severe primary pulmonary disease such as cor pulmonale * expected to undergo cardiac transplantation within one year (status i) * patients with a life expectancy of less than one year from non-cardiac cause. * patients included in other clinical trials that will affect the objectives of this study * those unable or unwilling to provide informed consent * those with a history of noncompliance to medical therapy